20-Oct-2020

CEO Dr James Garner interview with Proactive Investors on GBM AGILE

We’re pleased to share a video interview with our CEO, Dr James Garner on Proactive Investors following the recent commencement of the GBM AGILE study, which will serve as the pivotal study for registration of our lead candidate, paxalisib.

06-Oct-2020

Ausbiz, The Wall Street Transcript and Stockhead media articles

Our CEO, Dr James Garner was recently interviewed on Ausbiz to discuss Kazia’s entitlement offer, with the company successfully completing the institutional component of the offer last week, which raised $16.4 million.